166 related articles for article (PubMed ID: 21951283)
1. 3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells.
Buommino E; Tirino V; De Filippis A; Silvestri F; Nicoletti R; Ciavatta ML; Pirozzi G; Tufano MA
Cell Prolif; 2011 Oct; 44(5):401-9. PubMed ID: 21951283
[TBL] [Abstract][Full Text] [Related]
2. 3-O-methylfunicone, a metabolite of Penicillium pinophilum, inhibits proliferation of human melanoma cells by causing G(2) + M arrest and inducing apoptosis.
Baroni A; De Luca A; De Filippis A; Petrazzuolo M; Manente L; Nicoletti R; Tufano MA; Buommino E
Cell Prolif; 2009 Aug; 42(4):541-53. PubMed ID: 19486013
[TBL] [Abstract][Full Text] [Related]
3. 3-O-methylfunicone produced by penicillium pinophilum affects cell motility of breast cancer cells, downregulating alphavbeta5 integrin and inhibiting metalloproteinase-9 secretion.
Buommino E; Boccellino M; De Filippis A; Petrazzuolo M; Cozza V; Nicoletti R; Ciavatta ML; Quagliuolo L; Tufano MA
Mol Carcinog; 2007 Nov; 46(11):930-40. PubMed ID: 17562555
[TBL] [Abstract][Full Text] [Related]
4. [Tricostantin A inhibits self-renewal of breast cancer stem cells in vitro].
Peng L; Li FX; Shao WF; Xiong JB
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct; 33(10):1421-6. PubMed ID: 24144739
[TBL] [Abstract][Full Text] [Related]
5. Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.
Buommino E; De Filippis A; Nicoletti R; Menegozzo M; Menegozzo S; Ciavatta ML; Rizzo A; Brancato V; Tufano MA; Donnarumma G
Invest New Drugs; 2012 Aug; 30(4):1343-51. PubMed ID: 21656164
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the stemness potency of
Yousefnia S; Ghaedi K; Seyed Forootan F; Nasr Esfahani MH
Tumour Biol; 2019 Aug; 41(8):1010428319869101. PubMed ID: 31423948
[TBL] [Abstract][Full Text] [Related]
7. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT.
Hu C; Li M; Guo T; Wang S; Huang W; Yang K; Liao Z; Wang J; Zhang F; Wang H
Phytomedicine; 2019 May; 58():152740. PubMed ID: 31005718
[TBL] [Abstract][Full Text] [Related]
8. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
Ma X; Zhang Y; Kang Y; Li L; Zheng W
Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
[TBL] [Abstract][Full Text] [Related]
10. ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.
Leccia F; Del Vecchio L; Mariotti E; Di Noto R; Morel AP; Puisieux A; Salvatore F; Ansieau S
Mol Cancer; 2014 Sep; 13():213. PubMed ID: 25216750
[TBL] [Abstract][Full Text] [Related]
11. Senescence evasion by MCF-7 human breast tumor-initiating cells.
Karimi-Busheri F; Rasouli-Nia A; Mackey JR; Weinfeld M
Breast Cancer Res; 2010; 12(3):R31. PubMed ID: 20525204
[TBL] [Abstract][Full Text] [Related]
12. 3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells.
Buommino E; Paoletti I; De Filippis A; Nicoletti R; Ciavatta ML; Menegozzo S; Menegozzo M; Tufano MA
Cell Prolif; 2010 Apr; 43(2):114-23. PubMed ID: 20447056
[TBL] [Abstract][Full Text] [Related]
13. CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs.
Ji P; Zhang Y; Wang SJ; Ge HL; Zhao GP; Xu YC; Wang Y
Oncol Rep; 2016 Jun; 35(6):3293-302. PubMed ID: 27109463
[TBL] [Abstract][Full Text] [Related]
14. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
15. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
16. AhR ligand Aminoflavone inhibits α6-integrin expression and breast cancer sphere-initiating capacity.
Brantley E; Callero MA; Berardi DE; Campbell P; Rowland L; Zylstra D; Amis L; Yee M; Simian M; Todaro L; Loaiza-Perez AI; Soto U
Cancer Lett; 2016 Jun; 376(1):53-61. PubMed ID: 26996297
[TBL] [Abstract][Full Text] [Related]
17. [Influence factors on the formation of mammospheres from breast cancer stem cells].
Huang MZ; Zhang FC; Zhang YY
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):500-4. PubMed ID: 18931713
[TBL] [Abstract][Full Text] [Related]
18. MicroR-760 suppresses cancer stem cell subpopulation and breast cancer cell proliferation and metastasis: By down-regulating NANOG.
Han ML; Wang F; Gu YT; Pei XH; Ge X; Guo GC; Li L; Duan X; Zhu MZ; Wang YM
Biomed Pharmacother; 2016 May; 80():304-310. PubMed ID: 27133070
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy.
Pervin S; Hewison M; Braga M; Tran L; Chun R; Karam A; Chaudhuri G; Norris K; Singh R
PLoS One; 2013; 8(1):e53287. PubMed ID: 23341935
[TBL] [Abstract][Full Text] [Related]
20. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
